Abstract
Excellent recent trials have demonstrated beyond reasonable doubt that beta-blockade started during convalescence from confirmed myocardial infarction reduces mortality in the next year or two by about a quarter. Similar confidence does not extend to the mechanisms of action, choice of drug, defining treatment criteria in relation to severity and age, or to the duration of treatment.